The estimated Net Worth of Matthew K Fust is at least $4.77 million dollars as of 20 March 2024. Mr. Fust owns over 60,000 units of Ultragenyx Pharmaceutical stock worth over $2,029,908 and over the last 17 years he sold RARE stock worth over $2,322,274. In addition, he makes $417,890 as Independent Director at Ultragenyx Pharmaceutical.
Sign up
Mr. Fust RARE stock SEC Form 4 insiders trading
Matthew has made over 41 trades of the Ultragenyx Pharmaceutical stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of RARE stock worth $1,255,200 on 20 March 2024.
The largest trade he's ever made was exercising 60,000 units of Ultragenyx Pharmaceutical stock on 20 March 2024 worth over $1,255,200. On average, Matthew trades about 2,753 units every 41 days since 2007. As of 20 March 2024 he still owns at least 36,036 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr. Fust stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Fust biography
Matthew K. Fust serves as Independent Director of the Company. He is a board member and advisor to life sciences companies. Mr. Fust retired as Executive Vice President of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003, Mr. Fust served as Chief Financial Officer at Perlegen Sciences, Inc., a biopharmaceutical company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust currently serves on the board of directors of Atara Biotherapeutics, Inc., Crinetics Pharmaceuticals, Inc. and MacroGenics, Inc. (“MacroGenics”), which are publicly traded biopharmaceutical companies. Mr. Fust has notified MacroGenics that he will not stand for re-election as a director of the company upon the expiration of his term at the MacroGenics 2020 annual meeting of stockholders. Mr. Fust also previously served on the board of directors of Sunesis Pharmaceuticals, Inc. from May 2005 to May 2017 and on the board of Dermira, Inc. from August 2014 to February 2020. Mr. Fust received a B.A. in accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
What is the salary of Matthew Fust?
As the Independent Director of Ultragenyx Pharmaceutical, the total compensation of Matthew Fust at Ultragenyx Pharmaceutical is $417,890. There are 12 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
How old is Matthew Fust?
Matthew Fust is 55, he's been the Independent Director of Ultragenyx Pharmaceutical since 2014. There are 16 older and 7 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
What's Matthew Fust's mailing address?
Matthew's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.
Insiders trading at Ultragenyx Pharmaceutical
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr et Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
What does Ultragenyx Pharmaceutical do?
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
What does Ultragenyx Pharmaceutical's logo look like?
Complete history of Mr. Fust stock trades at Atara Biotherapeutics Inc, Jazz Pharmaceuticals plc, Macrogenics Inc, Ultragenyx Pharmaceutical et Crinetics Pharmaceuticals Inc
Ultragenyx Pharmaceutical executives and stock owners
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include:
-
Emil Kakkis,
President, Chief Executive Officer, Director -
Dennis Huang,
Chief Technical Operations Officer, Executive Vice President -
John Pinion,
Chief Quality Officer and Executive Vice President of Translational Sciences -
Camille Bedrosian,
Chief Medical Officer and Executive Vice President -
Thomas Kassberg,
Chief Business Officer, Executive Vice President -
Karah Parschauer,
Executive Vice President, General Counsel -
Dr. Emil D. Kakkis M.D., Ph.D.,
Pres, CEO & Director -
Shehnaaz Suliman,
Independent Director -
Dr. Camille L. Bedrosian M.D.,
Chief Medical Officer & Exec. VP -
Erik Harris,
Exec. VP & Chief Commercial Officer -
John Richard Pinion II,
Chief Quality Operations Officer & Exec. VP of Translational Sciences -
Daniel Welch,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
William Aliski,
Independent Director -
Michael Narachi,
Independent Director -
Lars Ekman,
Independent Director -
Clay Siegall,
Independent Director -
Deborah Dunsire,
Independent Director -
Mardi C. Dier,
Exec. VP & CFO -
Mardi Dier,
Chief Financial Officer, Executive Vice President -
Ernie Meyer,
Chief Human Resource Officer, Executive Vice President -
Erik Harris,
Executive Vice President and Chief Commercial Officer -
Ernie W. Meyer,
Chief HR Officer & Exec. VP -
Karah Herdman Parschauer J.D.,
Gen. Counsel & Exec. VP -
Danielle Keatley,
Sr. Director of Investor Relations & Corp. Communications -
Dennis Karl Huang,
Chief Technical Operations Officer & Exec. VP -
Theodore A. Huizenga,
VP, Corp. Controller & Principal Accounting Officer -
Sunil Agarwal,
Chief Medical Officer -
Jayson Donald Alexander Dallas,
See Remarks -
Wladimir Hogenhuis,
Chief Operating Officer -
Llc Fmr,
10% owner -
Marten Steen,
Director -
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Amrit Ray,
-
Shalini Sharp,
EVP, Finance -
Corazon (Corsee) D. Sanders,
-
Theodore Alan Huizenga,
SVP, Chief Accounting Officer -
Eric Crombez,
EVP and Chief Medical Officer -
Howard Horn,
Chief Financial Officer